Compare Novavax Inc (NVAX) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs SpaceX — how do they compare? Novavax Inc trades at $7.94 (market cap $1.31B), while SpaceX trades at $148.05 (market cap $1.76T). The key difference: SpaceX is far larger — about 1343.5× Novavax Inc's market cap. Which is the better fit depends on your goals.
| NVAX | SPCX | |
|---|---|---|
Market Cap | $1.31B | $1.76T |
Sector | Health | Technology |
52-Week High | $11.19 | $202.09 |
52-Week Low | $6.22 | $108.27 |
Enterprise Value | $889.30M | $1.70T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
SPCX stock trades at $147.99, up 6.67% today, with a bullish technical signal and strong analyst support. Recent news highlights AI growth and a $1.2 billion stake by Norway's sovereign wealth fund. However, the company shows negative net income margins and high valuation ratios, with revenue growth offset by profitability challenges.
The outlook is mixed: bullish sentiment and AI expansion offer upside, but high valuation and persistent losses pose risks. The consensus price target of $228.52 suggests potential growth, yet investors must weigh innovation against financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
